by Sue Robbins | Nov 12, 2020 | Migraine
Novartis announced positive results from a phase 4 study comparing treatment with erenumab (Aimovig), a calcitonin gene-related peptide (CGRP) receptor antagonist, to topiramate in patients with episodic and chronic migraine. The randomized, double-blind,...
by Sue Robbins | Jul 28, 2020 | Migraine
In patients with episodic migraine, erenumab provided sustained efficacy for the condition over the course of 1 year, according to new results from a study to evaluate the efficacy and safety of erenumab in migraine prevention (STRIVE), published in Neurology....
by Dr Robbins | Jul 30, 2019 | Migraine
The article by Depre and colleagues demonstrated that the new migraine preventive erenumab may be safe for stable angina patients. Loading... Taking too long? Reload document | Open in new...
by Dr Robbins | Jul 12, 2019 | Headache Drugs, Migraine
This is a new letter to the editor that I wrote, in the journal Headache; these newer CGRP meds are marvelous for many patients, but the true side effect profile is just evolving: (LETTER FROM THE JOURNAL HEADACHE, JULY, 2019: LAWRENCE ROBBINS,M.D.) Erenumab, the...
by Sue Robbins | Jun 19, 2019 | Migraine
For people with episodic migraine whose previous prophylactic treatments have failed, erenumab may represent an efficacious and tolerable treatment, according to a study recently published in the journal Cephalalgia. Placebo response rate was found to be lower among...